Market Newsdesk

March 31, 2021 9:34 pm

Sensata Technologies Holding plc Announces Pricing of the Offering of an Additional $250 Million of 4.000% Senior Notes due 2029 by Sensata Technologies B.V.

Sensata Technologies Holding plc Announces Pricing of the Offering of an Additional $250 Million of 4.000% Senior Notes due 2029 by Sensata Technologies B.V.

SWINDON, England–(BUSINESS WIRE)–
Sensata Technologies Holding plc (NYSE: ST) (“Sensata Technologies”) today announced that its indirect wholly owned subsidiary Sensata Technologies B.V. (the “Issuer”) priced the offering of an additional $250 million in aggregate principal amount of its 4.000% senior notes due 2029 (the “Additional Notes”) in a private offering that is exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”). The Additional Notes were priced at 100.75%. The closing of the offering is expected to occur on April 8, 2021, subject to customary closing conditions.

The Additional Notes will be issued under the indenture governing the Issuer’s existing 4.000% senior notes due 2029 and will be consolidated and form a single class with the $750 million aggregate principal amount of these notes that were issued by the Issuer on March 29, 2021 (the “Initial Notes” and, together with the Additional Notes, the “Notes”). The Additional Notes will have the same terms as the Initial Notes, other than with respect to the date of issuance and the issue price, and will be fungible with the Initial Notes immediately upon issuance.

The Notes are guaranteed on a senior unsecured basis by each of the Issuer’s wholly owned subsidiaries that is the borrower or a guarantor under Sensata’s senior credit facilities and the issuer or a guarantor under Sensata’s outstanding series of existing notes. The Notes and the guarantees are the Issuer’s and the guarantors’ senior unsecured obligations and rank equally in right of payment to all existing and future senior unsecured indebtedness of the Issuer or the guarantors, respectively, including the senior credit facilities and outstanding series of existing notes. The Notes and the guarantees are senior to all of the Issuer’s and the guarantors’ future indebtedness that is expressly subordinated to the Notes and the guarantees. The Notes and the guarantees are effectively junior to the Issuer’s and the guarantors’ existing and future secured indebtedness to the extent of the value of the assets securing such indebtedness, including indebtedness under the senior credit facilities, and are structurally subordinated to all of the existing and future obligations of any of the Issuer’s subsidiaries that do not guarantee the Notes.

Sensata Technologies intends to use the net proceeds from the offering of the Additional Notes for general corporate purposes, which may include working capital, capital expenditures, the acquisition of other companies, businesses or assets, strategic investments, the refinancing or repayment of debt, and share repurchases.

The Additional Notes and the related guarantees will be offered only to persons reasonably believed to be “qualified institutional buyers” in reliance on the exemption from registration provided by Rule 144A under the Securities Act and to non-U.S. persons outside of the United States in compliance with Regulation S under the Securities Act. The Additional Notes and the related guarantees have not been and will not be registered under the Securities Act, or the securities laws of any state or other jurisdiction, and may not be offered or sold in the United States without registration or an applicable exemption from the registration requirements of the Securities Act and applicable state securities or blue sky laws or outside the United States except in compliance with foreign securities laws.

Any Additional Notes that are issued pursuant to Regulation S under the Securities Act will trade under different CUSIP/ISIN numbers until 40 days after the issue date of such Additional Notes but thereafter may be transferred into the same CUSIP/ISIN numbers assigned to the Initial Notes that were issued pursuant to Regulation S.

This press release is for informational purposes only and shall not constitute an offer to sell or a solicitation of an offer to buy the Additional Notes or any other securities. The offering of Additional Notes is not being made to any person in any jurisdiction in which the offer, solicitation or sale is unlawful. Any offers of the Additional Notes will be made only by means of a private offering memorandum.

About Sensata Technologies

Sensata Technologies is a leading industrial technology company that develops sensors, sensor-based solutions, including controllers and software, and other mission-critical products to create valuable business insights for customers and end users. For more than 100 years, Sensata has provided a wide range of customized, sensor-rich solutions that address complex engineering requirements to help customers solve difficult challenges in the automotive, heavy vehicle & off-road, industrial and aerospace industries. With more than 19,000 employees and operations in 12 countries, Sensata’s solutions help to make products safer, cleaner and more efficient, more electrified, and more connected.

Safe Harbor Statement

Statements in this release which are not historical facts, such as those that may be identified by the use of words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “feel,” “forecast,” “intend,” “may,” “plan,” “potential,” “project,” “should,” “would,” and similar expressions, are forward-looking statements under the provisions of the Private Securities Litigation Reform Act of 1995. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. These risks and uncertainties include, but are not limited to, the consummation of the offering by the Issuer and the use of proceeds. Detailed information about some of the other known risks is included in our Annual Report on Form 10-K for the year ended December 31, 2020 and our other reports filed with the Securities and Exchange Commission. Because actual results could differ materially from our intentions, plans, expectations, assumptions and beliefs about the future, you are urged to view all forward-looking statements contained in this news release with caution. Except as required by applicable law, we do not undertake to publicly update or revise any of these forward-looking statements, whether as a result of new information, future events, or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210331006058/en/

Media Contact:

Alexia Taxiarchos

Head of Media Relations

+1 (508) 236-1761

[email protected]

Investor Contact:

Jacob Sayer

Vice President, Finance

+1 (508) 236-1666

[email protected]

KEYWORDS: United Kingdom Europe

INDUSTRY KEYWORDS: Software Technology Hardware Semiconductor

MEDIA:

Logo

March 31, 2021 9:30 pm

ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Clover Health Investments, Corp. f/k/a Social Capital Hedosophia Holdings Corp. III Investors With Losses in Excess of $100K to Secure Counsel Before Important Tuesday Deadline in Securities Class Action – CLOV, CLOVW, IPOC

PR Newswire

NEW YORK, March 31, 2021 /PRNewswire/ —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Clover Health Investments, Corp. f/k/a Social Capital Hedosophia Holdings Corp. III (NASDAQ: CLOV, CLOVW) (NYSE: IPOC) who: (1) purchased or otherwise acquired publicly traded Clover securities between October 6, 2020 and February 4, 2021, inclusive (the “Class Period”); and/or (2) purchased or otherwise acquired Clover securities pursuant or traceable to the registration statement and prospectus issued in connection with the December 2020 merger of Clover and Social Capital III of the important April 6, 2021 lead plaintiff deadline.

SO WHAT: If you purchased Clover securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Clover class action, go to http://www.rosenlegal.com/cases-register-2030.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action. If you wish to serve as lead plaintiff, you must move the Court no later than April 6, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience or resources. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020 founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period and in the registration statement made false and/or misleading statements and/or failed to disclose that: (1) Clover’s Clover Assistant platform was under active investigation by the Department of Justice (“DOJ”) for at least 12 issues ranging from kickbacks to marketing practices to undisclosed third-party deals; (2) the DOJ’s investigation presented an existential risk to the Company, since it derives most of its revenues from Medicare; (3) Clover’s sales were driven by a major undisclosed related party deal and misleading marketing targeting the elderly, not its purported “best-in-class” technology; (4) a significant portion of Clover’s sales were by way of an undisclosed relationship between Clover and an outside brokerage firm controlled by Clover’s Head of Sales; and (5) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Clover class action, go to http://www.rosenlegal.com/cases-register-2030.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40^th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      [email protected]
      [email protected]
      www.rosenlegal.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/rosen-respected-investor-counsel-encourages-clover-health-investments-corp-fka-social-capital-hedosophia-holdings-corp-iii-investors-with-losses-in-excess-of-100k-to-secure-counsel-before-important-tuesday-deadline-in-secu-301260162.html

SOURCE Rosen Law Firm, P.A.

March 31, 2021 9:03 pm

Royal Caribbean Extends Singapore Season, Adding New Cruises On Quantum Of The Seas

With More Than 50,000 Guests Safely Sailing on Board to Date, Holidaymakers are Eager for More Adventure

PR Newswire

SINGAPORE, March 31, 2021 /PRNewswire/ — Royal Caribbean International today announced Quantum of the Seas will continue sailing from Singapore through October 2021. Having resumed sailing in December 2020, Quantum’s 11-month Singapore season will mark the longest yet for one of Asia’s largest and most revolutionary cruise ships. The cruise line introduced Ocean Getaways from Singapore last year with the local government’s CruiseSafe Certification, which confirms the sailings meet the comprehensive health and safety requirements developed with the Singapore government. Following a successful run and high marks from guests, Royal Caribbean first extended the season for three months, through June 2021, and is doing it again for an additional four months thanks to the partnership with the Singapore government.

“We have continued to see an overwhelming demand in Singapore to sail on board Quantum of the Seas. With more than 50,000 guests having cruised with us and zero positive COVID-19 cases to date, holidaymakers can rest assured we are focused on delivering safe, memorable cruise holidays,” said Michael Bayley, president and CEO, Royal Caribbean International. “Royal Caribbean’s 30-plus sailings in Singapore offer a real-life, validated model of how cruising can be a unique, safe vacation beyond what many other travel options can offer. I’m confident we’ll continue to see how successful cruising can be through a combination of our proven, healthy and safe practices, which are informed by the Healthy Sail Panel’s 74 recommendations, and the rollout of vaccines around the world.”

Singapore residents can continue to satisfy their feelings of wanderlust on 2-, 3- and 4-night Ocean Getaways and enjoy fun-filled activities, next-generation entertainment and world-class dining on board one of Royal Caribbean’s most groundbreaking ships. These new sailings will be available to Singapore residents and open to book on April 13, 2021.

“Our guests have continued to have a fabulous vacation experience with Royal Caribbean, as we continue sailing with our layered health and safety measures developed with the Healthy Sail Panel. In fact, we have seen guest satisfaction ratings jump since we started sailing this past December,” said Angie Stephen, vice president and managing director, Asia-Pacific, Royal Caribbean International.

Quantum
will continue to operate with the same set of comprehensive health and safety measures in place, such as COVID-19 testing, reduced sailing capacity, physical distancing measures, enhanced cleaning and sanitizing processes, and industry-leading contact tracing.

“When we started pilot cruises in Singapore, our aim was to regain the confidence of guests by endorsing cruise operators with rigorous hygiene measures. Singapore’s CruiseSafe standards have set a clear benchmark for our cruise partners, who have been diligent in ensuring the measures on board are adhered to. Thus far, we have completed more than 90 sailings with over 120,000 passengers and no reported cases of COVID-19 spreading on board,” said Annie Chang, Director, Cruise, Singapore Tourism Board.

As the broader travel and tourism industry reopens around the world, holidaymakers who are looking for an adventure can be confident in cruise ship safety. Since July 2020, Royal Caribbean Group has carried more than 100,000 guests on 152 cruises in Asia and Europe. This extension follows months of successful cruises in Singapore, with more than 50,000 guests who have sailed aboard Quantum to date, as well as the recently announced plans for the highly anticipated Odyssey of the Seas to cruise from Haifa, Israel, Jewel of the Seas sailing from Cyprus, Anthem of the Seas sailing from the UK and cruises from The Bahamas with Adventure of the Seas and Bermuda with Vision of the Seas.

About Royal Caribbean International

Royal Caribbean International has been delivering innovation at sea for more than 50 years. Each successive class of ships is an architectural marvel featuring the latest technology and guest experiences for today’s adventurous traveler. The cruise line continues to revolutionize vacations with itineraries to more than 270 destinations in 72 countries on six continents, including Royal Caribbean’s private island destination in The Bahamas, Perfect Day at CocoCay, the first in the Perfect Day Island Collection. Royal Caribbean has also been voted “Best Cruise Line Overall” for 18 consecutive years in the Travel Weekly Readers’ Choice Awards.

Media can stay up to date by following @RoyalCaribPR on Twitter and visiting RoyalCaribbeanPressCenter.com. For additional information or to make reservations, vacationers can call their travel advisor; visit RoyalCaribbean.com; or call (800) ROYAL-CARIBBEAN.

Royal Caribbean International is applying the recommendations of its Healthy Sail Panel of public health and scientific experts to provide a safer and healthier cruise vacation on all of its sailings. Health and safety protocols, regional travel restrictions and clearance to visit ports of call, are subject to change based on ongoing evaluation, public health standards, and government requirements. U.S. cruises and guests: For more information on the latest health and travel alerts, U.S. government travel advisories, please visit www.royalcaribbean.com/cruise-ships/itinerary-updates or consult travel advisories, warnings or recommendations relating to cruise travel on applicable government websites.

View original content to download multimedia:http://www.prnewswire.com/news-releases/royal-caribbean-extends-singapore-season-adding-new-cruises-on-quantum-of-the-seas-301260187.html

SOURCE Royal Caribbean International

March 31, 2021 9:03 pm

RRC INVESTOR NOTICE: ROSEN, A TOP RANKED LAW FIRM, Encourages Range Resources Corporation Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline – RRC

PR Newswire

NEW YORK, March 31, 2021 /PRNewswire/ —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Range Resources Corporation (NYSE: RRC) between April 29, 2016 and February 10, 2021, inclusive (the “Class Period”), of the important May 3, 2021 lead plaintiff deadline.

SO WHAT: If you purchased Range Resources securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Range Resources class action, go to http://www.rosenlegal.com/cases-register-2053.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 3, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Range Resources had improperly designated the status of its wells in Pennsylvania since at least 2013; (2) the foregoing conduct subjected the Company to a heightened risk of regulatory investigation and enforcement, as well as artificially decreased the Company’s periodically reported cost estimates to plug and abandon its wells; (3) the Company was the subject of a Pennsylvania Department of Environmental Protection (“DEP”) investigation from sometime between September 2017 to January 2021 for improperly designating the status of its wells; (4) the DEP investigation foreseeably would and ultimately did lead to the Company incurring regulatory fines; and (5) as a result, the Company’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Range Resources class action, go to http://www.rosenlegal.com/cases-register-2053.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      [email protected]
      [email protected]
      www.rosenlegal.com

View original content:http://www.prnewswire.com/news-releases/rrc-investor-notice-rosen-a-top-ranked-law-firm-encourages-range-resources-corporation-investors-with-losses-exceeding-100k-to-secure-counsel-before-important-deadline–rrc-301260142.html

SOURCE Rosen Law Firm, P.A.

March 31, 2021 9:03 pm

REPRO MED ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Repro Med Systems, Inc. and Encourages Investors to Contact the Firm

REPRO MED ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Repro Med Systems, Inc. and Encourages Investors to Contact the Firm

NEW YORK–(BUSINESS WIRE)–
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of investors that purchased Repro Med Systems, Inc. d/b/a KORU Medical Systems (NASDAQ: KRMD) securities between August 4, 2020 and January 25, 2021, inclusive (the “Class Period”). Investors have until May 25, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Click here to participate in the action.

KORU designs, manufactures, and markets proprietary portable medical devices, primarily for the ambulatory infusion market.

On November 3, 2020, after the market closed, KORU announced its third quarter 2020 financial results, reporting that net sales declined sequentially to $6.1 million. During the conference call the next day, the Company attributed the lower sales to, among other things, “higher allowances for gross rebates for certain customers” and “payment discounts and distribution fees.”

On this news, the Company’s stock fell $1.97, or 32%, to close at $4.16 per share on November 4, 2020.

On January 25, 2021, after the market closed, KORU announced its preliminary financial results for fiscal 2020, expecting revenue of approximately $24.0 million, an increase of 3.4% over the prior year. The Company attributed the results to, among other things, “[s]lower growth in net revenue as a result of strengthening our contractual position with large customers.” In the press release, KORU also announced that its CEO, Donald Pettigrew, resigned, effective immediately.

On this news, KORU’s stock price fell $0.80 per share, or 15.5%, to close at $4.33 per share on January 26, 2021.

The complaint, filed on March 26, 2021, alleges that throughout the Class Period defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, defendants failed to disclose to investors that: (1) starting in January 2020, KORU ramped up the use of allowances, including growth rebates, to retain key customers and to incentivize growth; (2) as the rebates accrued, the Company’s net sales were reasonably likely to decline; and (3) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

If you purchased Repro Med securities during the Class Period and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker, Melissa Fortunato, or Marion Passmore by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210331006001/en/

Bragar Eagel & Squire, P.C.

Brandon Walker, Esq.

Melissa Fortunato, Esq.

Marion Passmore, Esq.

(212) 355-4648

[email protected]

www.bespc.com

KEYWORDS: California New York United States North America

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo

March 31, 2021 9:03 pm

UBIQUITI ALERT: Bragar Eagel & Squire, P.C. is Investigating Ubiquiti, Inc. on Behalf of Ubiquiti Stockholders and Encourages Investors to Contact the Firm

UBIQUITI ALERT: Bragar Eagel & Squire, P.C. is Investigating Ubiquiti, Inc. on Behalf of Ubiquiti Stockholders and Encourages Investors to Contact the Firm

NEW YORK–(BUSINESS WIRE)–
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Ubiquiti, Inc. (NYSE: UI) on behalf of Ubiquiti stockholders. Our investigation concerns whether Ubiquiti has violated the federal securities laws and/or engaged in other unlawful business practices.

Click here to participate in the action.

On January 11, 2021, Ubiquiti disclosed that a breach involving a third-party cloud provider had exposed customer account credentials.

On this news, Ubiquiti’s share price fell $13.69 per share, or 5%, over the next two trading days.

Then on March 30, 2021, the Krebs on Security posted an article entitled “Whistleblower: Ubiquiti Breach ‘Catastrophic’” stating that “[n]ow a source who participated in the response to that breach alleges Ubiquiti massively downplayed a ‘catastrophic’ incident to minimize the hit to its stock price, and that the third-party cloud provider claim was a fabrication.” Further, the article quoted a letter from the source to the European Data Protection Supervisor stating “[i]t was catastrophically worse than reported, and legal silenced and overruled efforts to decisively protect customers” and “[t]he breach was massive, customer data was at risk, access to customers’ devices deployed in corporations and homes around the world was at risk.”

On this news, Ubiquiti’s share price fell on March 30, 2021, to close at $349.00 per share.

If you purchased or otherwise acquired Ubiquiti shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker, Melissa Fortunato, or Marion Passmore by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:

View source version on businesswire.com: https://www.businesswire.com/news/home/20210331005984/en/

Bragar Eagel & Squire, P.C.

Brandon Walker, Esq.

Melissa Fortunato, Esq.

Marion Passmore, Esq.

(212) 355-4648

[email protected]

www.bespc.com

KEYWORDS: California New York United States North America

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo

March 31, 2021 9:03 pm

CANOO ALERT: Bragar Eagel & Squire, P.C. is Investigating Canoo, Inc. on Behalf of Canoo Stockholders and Encourages Investors to Contact the Firm

CANOO ALERT: Bragar Eagel & Squire, P.C. is Investigating Canoo, Inc. on Behalf of Canoo Stockholders and Encourages Investors to Contact the Firm

NEW YORK–(BUSINESS WIRE)–
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Canoo, Inc. (NASDAQ: GOEV) on behalf of Canoo stockholders. Our investigation concerns whether Canoo has violated the federal securities laws and/or engaged in other unlawful business practices.

Click here to participate in the action.

On March 29, 2021, Canoo announced its fourth quarter and full year 2020 financial results in a press release, reporting a net loss of $89.9 million for the year. The Company also announced that its Chief Financial Officer had resigned.

The same day, The Verge released an article entitled “Canoo’s deal with Hyundai appears dead: The startup’s [sic] also changed its tune on selling EV tech to big companies.” The article stated that “[w]hen pressed on the startup’s previous claims,” the current chairman pointed to its prior leadership and said “they were a little more aggressive” and “that talk of potential partnerships was ‘presumptuous.’” Lastly, the article noted that “Canoo quietly uploaded a new investor presentation to its investor relations website on Monday that no longer mentions Hyundai.”

On this news, Canoo’s share price fell sharply on March 30, 2021, thereby damaging investors.

If you purchased or otherwise acquired Canoo shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker, Melissa Fortunato, or Marion Passmore by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:

View source version on businesswire.com: https://www.businesswire.com/news/home/20210331005978/en/

Bragar Eagel & Squire, P.C.

Brandon Walker, Esq.

Melissa Fortunato, Esq.

Marion Passmore, Esq.

(212) 355-4648

[email protected]

www.bespc.com

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo

March 31, 2021 9:03 pm

SOS LIMITED ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against SOS Limited and Encourages Investors to Contact the Firm

SOS LIMITED ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against SOS Limited and Encourages Investors to Contact the Firm

NEW YORK–(BUSINESS WIRE)–
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the District of New Jersey on behalf of investors that purchased SOS Limited (NYSE: SOS) American Depositary Shares (“ADSs”) between July 22, 2020 and February 25, 2021, inclusive (the “Class Period”). Investors have until June 1, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Click here to participate in the action.

When the Company went public in April 2017, it was known as “China Rapid Finance Limited” and claimed to focus on a peer-to-peer, micro-lending business. The Company later changed its name to “SOS Limited” in July 2020 and sold its peer-to-peer, micro-lending business in August 2020, rebranding itself into an emergency services business. In January 2021, the Company again shifted its business focus, this time to cryptocurrency mining.

Critical to SOS’s purportedly successful transition into a cryptocurrency mining business were the Company’s claims to have entered into an agreement with HY International Group New York Inc. (“HY”), which calls itself the “world’s largest mining machine matchmaker,” to acquire 15,645 mining rigs—i.e., personal computing machines built specifically for cryptocurrency mining—for $20 million, and the Company’s plans to purchase FXK Technology Corporation (“FXK”), a purported Canadian cryptocurrency technology firm.

On February 26, 2021, Hindenburg Research (“Hindenburg”) and Culper Research (“Culper”) released commentary on SOS, claiming that the Company was an intricate “pump and dump” scheme that used fake addresses and doctored photos of crypto mining rigs to create an illusion of success. The analysts noted, for example, that SOS’s SEC filings listed a hotel room as the Company’s headquarters. The analysts also questioned whether SOS had actually purchased mining rigs that it claimed to own, as the entity from which SOS purportedly bought the mining rigs appeared to be a fake shell company. The analysts further alleged that the photos SOS had published of their purported “mining rigs” were phony. Culper noted that photographs of SOS’s “miners” did not depict the A10 Pro machines that the Company claimed to own and instead appeared to show different devices altogether. Hindenburg, for its part, found that the original images from SOS’s website actually belonged to another company.

On this news, SOS’s American depositary share price fell $1.27 per share, or 21.03%, to close at $4.77 per ADS on February 26, 2021.

The complaint, filed on March 30, 2021, alleges that, throughout the Class Period defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) SOS had misrepresented the true nature, location, and/or existence of at least one of the principal executive offices listed in its SEC filings; (ii) HY and FXK were either undisclosed related parties and/or entities fabricated by the Company; (iii) the Company had misrepresented the type and/or existence of the mining rigs that it claimed to have purchased; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

If you purchased SOS ADSs during the Class Period and suffered a loss, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker, Melissa Fortunato, or Marion Passmore by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:

View source version on businesswire.com: https://www.businesswire.com/news/home/20210331005827/en/

Bragar Eagel & Squire, P.C.

Brandon Walker, Esq.

Melissa Fortunato, Esq.

Marion Passmore, Esq.

(212) 355-4648

[email protected]

www.bespc.com

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo

March 31, 2021 8:49 pm

Applied Molecular Transport Announces Pricing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., March 31, 2021 (GLOBE NEWSWIRE) — Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 2,500,000 shares of its common stock at a public offering price of $42.00 per share. All of the shares of common stock are being offered by AMT. In addition, AMT has granted the underwriters a 30-day option to purchase up to an additional 375,000 shares of its common stock at the public offering price, less the underwriting discounts and commissions. The gross proceeds to AMT from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by AMT, are expected to be $105.0 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on April 6, 2021, subject to the satisfaction of customary closing conditions.

BofA Securities, Jefferies, and SVB Leerink are acting as joint book-running managers for the offering.

The registration statement relating to these securities became effective on March 31, 2021. The offering is made only by means of a prospectus, copies of which may be obtained from BofA Securities, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or by email at [email protected]; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 821-7388, or by email at [email protected]; or SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by telephone at (800) 808-7525, ext. 6105, or by email at [email protected]. Copies of the final prospectus, when available, related to the offering will be available at www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Applied Molecular Transport Inc.

Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company leveraging its proprietary technology platform to design and develop a pipeline of novel oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. AMT’s proprietary technology platform allows it to exploit existing natural cellular trafficking pathways to facilitate the active transport of diverse therapeutic modalities across the intestinal epithelium (IE) barrier. Active transport is an efficient mechanism that uses the cell’s own machinery to transport materials across the IE barrier. AMT believes that its ability to exploit this mechanism is a key differentiator of its approach. AMT is developing additional oral biologic product candidates in patient-friendly oral forms that are designed to either target local gastrointestinal tissue or enter systemic circulation to precisely address the relevant biology of a disease.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on AMT’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause AMT’s actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Such forward-looking statements include, among other things, statements regarding the timing, size and completion of the public offering of common stock. The forward-looking statements contained herein are based upon AMT’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the offering, and other risks. These and other risks are described more fully in AMT’s registration statement on Form S-1 filed with the U.S. Securities and Exchange Commission (“SEC”) on March 29, 2021 and the prospectus included therein, as well as AMT’s other filings with the SEC from time to time, including its Annual Report on Form 10-K filed with the SEC on March 19, 2021. Except to the extent required by law, AMT undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Investor Relations Contact:

Andrew Chang
Head, Investor Relations & Corporate Communications
[email protected]

Media Contacts:

Alexandra Santos
Wheelhouse Life Science Advisors
[email protected]

Aljanae Reynolds
Wheelhouse Life Science Advisors
[email protected]

March 31, 2021 8:48 pm

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages SOS Limited Investors to Secure Counsel Before Important Deadline – SOS

PR Newswire

NEW YORK, March 31, 2021 /PRNewswire/ —

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of SOS Limited (NYSE: SOS) between July 22, 2020 and February 25, 2021, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 1, 2021.

SO WHAT: If you purchased SOS securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the SOS class action, go to http://www.rosenlegal.com/cases-register-2070.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 1, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose information that resulted in a scheme that: (1) SOS had misrepresented the true nature, location, and/or existence of at least one of its principal executive offices listed in its SEC filings; (2) HY International Group New York Inc. and FXK Technology Corporation were either undisclosed related parties and/or entities fabricated by the Company; (3) the Company had misrepresented the type and/or existence of the mining rigs that it claimed to have purchased; and (4) as a result, the Company’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the SOS class action, go to http://www.rosenlegal.com/cases-register-2070.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

View original content to download multimedia:http://www.prnewswire.com/news-releases/rosen-a-global-and-leading-law-firm-encourages-sos-limited-investors-to-secure-counsel-before-important-deadline–sos-301260140.html

SOURCE Rosen Law Firm, P.A.